Gerald A Beltz

US Patent:

6645495, Nov 11, 2003

Filed:

Aug 28, 1998

Appl. No.:

09/143145

Inventors:

Charlotte A. Kensil - Milford MA
Gerald A. Beltz - Lexington MA

Assignee:

Antigenics, Inc. - Woburn MA

International Classification:

A61K 3900

US Classification:

4241841, 4242781, 4242831, 514 44

Abstract:

Certain novel compositions of the adjuvant saponin QS-21 having improved properties are disclosed. The compositions of the present invention are designed (1) to minimize the lytic effects of QS-21, (2) to improve the tolerance of QS-21 containing formulations in humans or other animals, (3) to stabilize the QS-21 from alkaline hydrolysis and/or (4) to maintain the high adjuvant potency of the QS-21 product. These compositions may be employed with vaccines comprising proteins or peptides, polysaccharides, lipids, or nucleic acids.

US Patent:

7863434, Jan 4, 2011

Filed:

Feb 26, 2001

Appl. No.:

09/792957

Inventors:

Cheryl Murphy - Hopkinton MA, US
James Storey - Lynwood MA, US
Gerald A. Beltz - Lexington MA, US
Richard T. Coughlin - Portland ME, US

Assignee:

Antigenics Inc. - Lexington MA

International Classification:

C07H 21/04
A61K 39/38
C12N 1/00

US Classification:

536 237, 536 231, 424 91, 424 92, 4241841, 435243, 4352521, 514 44

Abstract:

The present invention relates, in general, to granulocytic ehrlichia (GE) proteins. In particular, the present invention relates to nucleic acid molecules coding for GE S2, S7, S22, S23, C6. 1, C6. 2, S11, E8, E46#1, and E46#2 proteins; purified GE S2, S7, S22, S23, C6. 1, C6. 2, S11, E8, E46#1, and E46#2 proteins and polypeptides; recombinant nucleic acid molecules; cells containing the recombinant nucleic acid molecules; antibodies having binding affinity specifically to GE S2, S7, S22, S23, C6. 1, C6. 2, S11, E8, E46#1, and E46#2 proteins and polypeptides; hybridomas containing the antibodies; nucleic acid probes for the detection of nucleic acids encoding GE S2, S7, S22, S23, C6. 1, C6. 2, S11, E8, E46#1, and E46#2 proteins; a method of detecting nucleic acids encoding GE S2, S7, S22, S23, C6. 1, C6. 2, S11, E8, E46#1, and E46#2 proteins or polypeptides in a sample; kits containing nucleic acid probes or antibodies; bioassays using the nucleic acid sequence, protein or antibodies of this invention to diagnose, assess, or prognose a mammal afflicted with ehrlichiosis; therapeutic uses, specifically vaccines comprising S2, S7, S22, S23, C6. 1, C6.

US Patent:

8093008, Jan 10, 2012

Filed:

Aug 18, 2010

Appl. No.:

12/859236

Inventors:

Cheryl Murphy - Hopkinton MA, US
James Storey - Lynwood MA, US
Gerald A. Beltz - Lexington MA, US
Richard T. Coughlin - Portland ME, US

Assignee:

Antigenics, Inc. - Lexington MA

International Classification:

G01N 33/53
A61K 39/02
A61K 39/00

US Classification:

435 71, 4241841, 4241851, 4241901, 435 72, 435243, 530300, 530350

Abstract:

The present invention relates, in general, to granulocytic ehrlichia (GE) proteins. In particular, the present invention relates to nucleic acid molecules coding for GE S2, S7, S22, S23, C6. 1, C6. 2, S11, E8, E46#1, and E46#2 proteins; purified GE S2, S7, S22, S23, C6. 1, C6. 2, S11, E8, E46#1, and E46#2 proteins and polypeptides; recombinant nucleic acid molecules; cells containing the recombinant nucleic acid molecules; antibodies having binding affinity specifically to GE S2, S7, S22, S23, C6. 1, C6. 2, S11, E8, E46#1, and E46#2 proteins and polypeptides; hybridomas containing the antibodies; nucleic acid probes for the detection of nucleic acids encoding GE S2, S7, S22, S23, C6. 1, C6. 2, S11, E8, E46#1, and E46#2 proteins; a method of detecting nucleic acids encoding GE S2, S7, S22, S23, C6. 1, C6. 2, S11, E8, E46#1, and E46#2 proteins or polypeptides in a sample; kits containing nucleic acid probes or antibodies; bioassays using the nucleic acid sequence, protein or antibodies of this invention to diagnose, assess, or prognose a mammal afflicted with ehrlichiosis; therapeutic uses, specifically vaccines comprising S2, S7, S22, S23, C6. 1, C6.

US Patent:

8435495, May 7, 2013

Filed:

Jun 25, 2012

Appl. No.:

13/532222

Inventors:

Cheryl Murphy - Hopkinton MA, US
James Storey - Lynwood MA, US
Gerald A. Beltz - Lexington MA, US
Richard T. Coughlin - Portland ME, US

Assignee:

Antigenics, Inc. - Lexington MA

International Classification:

A61K 49/00

US Classification:

424 91, 424 92, 4241841, 435243, 4352521, 530300, 530350

Abstract:

The present invention relates, in general, to methods of screening a sample obtained from a subject for antibodies relating to granulocytic ehrlichia (GE) infection.

US Patent:

8461323, Jun 11, 2013

Filed:

Jan 9, 2012

Appl. No.:

13/346088

Inventors:

Cheryl Murphy - Hopkinton MA, US
James Storey - Lynwood MA, US
Gerald A. Beltz - Lexington MA, US
Richard T. Coughlin - Portland ME, US

Assignee:

Antigenics, Inc. - Lexington MA

International Classification:

C07H 21/04
A61K 39/02
G01N 33/53

US Classification:

536 237, 4241841, 4241851, 4241901, 4242341, 435 72, 435243, 530300, 530350

Abstract:

The present invention relates, in general, to polypeptides having antigenic epitopes from granulocytic ehrlichia (GE) proteins and methods of use thereof.

US Patent:

20020044951, Apr 18, 2002

Filed:

Apr 4, 2001

Appl. No.:

09/825789

Inventors:

Gui Liu - Medford MA, US
Gerald Beltz - Lexington MA, US
Kenneth LeClair - Needham MA, US
Daniel Cox - Medway MA, US
Charlotte Kensil - Milford MA, US

International Classification:

A61K039/02
A61K031/715

US Classification:

424/264100, 514/054000

Abstract:

Nonpeptide antigens were isolated and purified from The antigens were used in vaccine compositions, pharmaceutical compositions and methods to elicit an immune response to in a mammal.

US Patent:

20050191310, Sep 1, 2005

Filed:

Oct 3, 2003

Appl. No.:

10/679708

Inventors:

Charlotte Kensil - Milford MA, US
Gerald Beltz - Lexington MA, US

International Classification:

A61K048/00
A61K039/00
A61K031/715
A61K031/724

US Classification:

424185100, 514025000, 514058000, 514054000, 514044000

Abstract:

Certain novel compositions of the adjuvant saponin QS-21 having improved properties are disclosed. The compositions of the present invention are designed (1) to minimize the lytic effects of QS-21, (2) to improve the tolerance of QS-21 containing formulations in humans or other animals, (3) to stabilize the QS-21 from alkaline hydrolysis and/or (4) to maintain the high adjuvant potency of the QS-21 product. These compositions may be employed with vaccines comprising proteins or peptides, polysaccharides, lipids, or nucleic acids.

US Patent:

53524497, Oct 4, 1994

Filed:

Apr 14, 1992

Appl. No.:

7/869082

Inventors:

Gerald A. Beltz - Lexington MA
Dante J. Marciani - Hopkinton MA
Chung-Ho Hung - Milford MA
Charlotte A. Kensil - Milford MA

Assignee:

Cambridge Biotech Corporation - Worcester MA

International Classification:

A61K 3939
A61K 3912

US Classification:

4241871

Abstract:

The invention relates to antigenic preparations useful for inducing the production of antibodies in a cat which will bind to epitopes on feline leukemia virus. Also disclosed are immunogenic compositions and methods for immunizing a cat to enable the production of antibodies to feline leukemia virus.

Address:

4 Eustis St, Lexington, MA 02421

Phone:

7815721090

VIN:

JTDBT923771017460

Make:

TOYOTA

Model:

YARIS

Year:

2007